HCC Surveillance Every 6 Months is the Most Appropriate Next Step
This patient requires immediate enrollment in hepatocellular carcinoma surveillance with liver ultrasound ± AFP every 6 months, regardless of his current treatment status. 1
Why HCC Surveillance Takes Priority
This 38-year-old man has two critical HCC risk factors that mandate surveillance:
- Family history of HCC (father died at age 60) - This is explicitly listed as a high-risk feature in multiple guidelines 1
- Chronic HBV infection - Even without cirrhosis, chronic HBV carriers are at elevated HCC risk 2, 3
The guidelines are unequivocal: all major hepatology societies (AASLD, APASL, EASL) recommend HCC surveillance with ultrasound every 6 months for patients with family history of HCC, regardless of whether they have cirrhosis 1. APASL specifically recommends adding AFP to ultrasound 1.
Why Not Start Antiviral Therapy Immediately?
This patient is likely in the HBeAg-positive chronic infection phase (formerly "immune tolerant"):
- HBeAg positive
- Normal ALT/AST
- Asymptomatic
- Age 38
Current guidelines do NOT recommend immediate antiviral treatment for this phase 1. Here's the algorithmic approach:
Treatment Decision Algorithm for HBeAg-Positive Patients:
If HBV DNA >20,000 IU/mL and ALT >2× ULN:
- Monitor 3-6 months
- Treat if no spontaneous HBeAg loss 1
If HBV DNA >20,000 IU/mL and ALT normal or 1-2× ULN:
- Monitor every 3-6 months
- Consider liver biopsy if:
- Treat if biopsy shows moderate/severe inflammation or significant fibrosis 1
Critical caveat: While this patient doesn't meet immediate treatment criteria based on ALT alone, his family history of HCC is a red flag. The 2014 guidelines specifically note that family history of HCC should prompt consideration of liver biopsy even in younger patients with borderline ALT 1. The most recent 2025 EASL guidelines emphasize that family history of HCC is a key risk factor that may justify earlier intervention 4.
What Needs to Happen Next
Immediate Actions:
- Enroll in HCC surveillance: Liver ultrasound ± AFP every 6 months 1, 2, 1
- Obtain HBV DNA level (not provided in the question but essential for treatment decisions)
- Monitor ALT every 3-6 months 1, 2, 1
Consider for Near-Term:
- Liver biopsy given family history of HCC, even though he's under 40 1
- If biopsy shows moderate/severe inflammation or significant fibrosis → start tenofovir 1
Why Other Options Are Wrong
Option A (Start Tenofovir immediately): Premature without knowing HBV DNA level and with normal ALT. Treatment in the immune tolerant phase has poor response rates and is not guideline-recommended 1.
Option B (Monitor ALT every 2 years only): Dangerously inadequate. Guidelines require 3-6 month ALT monitoring for HBeAg-positive patients 1, 2, 1.
Option C (Liver transplant evaluation): Absurd for an asymptomatic patient with normal liver function and no cirrhosis.
Option E (Repeat serology annually): Misses the point entirely. HCC surveillance is the priority, not serological monitoring.
The Bottom Line
HCC surveillance is non-negotiable for this patient due to his family history. The evidence shows that family history of HCC significantly increases risk even in younger patients without cirrhosis 2, 5. One prospective study found that 15.8% of cirrhotic patients and 6.0% of chronic hepatitis patients developed HCC over 7 years of follow-up 5. Another study demonstrated that patients with family history of HCC require more aggressive monitoring and earlier consideration of treatment 6.
The answer is D: Follow-up with liver ultrasound ± AFP every 6 months. This addresses the most immediate mortality risk (HCC) while allowing time to properly assess whether antiviral therapy is indicated based on complete virological data and possibly liver biopsy findings.